Iovance Biotherapeutics Inc. Stock
Heavy losses for Iovance Biotherapeutics Inc. today as the stock fell by -€0.060 (-3.090%).
With 17 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 15 € there is potential for a 699.06% increase which would mean more than doubling the current price of 1.88 € for Iovance Biotherapeutics Inc..
So far the community has only identified positive things for Iovance Biotherapeutics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Iovance Biotherapeutics Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Iovance Biotherapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc. | -3.090% | 2.465% | -5.304% | -76.280% | -71.952% | -70.459% | -95.240% |
| Ironwood Pharmaceuticals | 3.290% | -3.797% | 84.242% | -12.644% | -27.619% | -72.543% | -69.293% |
| Novocure Ltd | 3.110% | 11.759% | 16.191% | -59.936% | -61.161% | -84.188% | -91.887% |
| Alnylam Pharmace. | -1.390% | -14.786% | -9.547% | 43.367% | 53.077% | 57.432% | 233.398% |
Comments
Iovance Biotherapeutics (NASDAQ:IOVA) had its price target lowered by analysts at HC Wainwright from $20.00 to $9.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $14.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for IOVA provided by MarketBeat